|
Family Studies
|
ZIA CP004410-08165
|
$419,608
|
$83,922
|
A Tucker, Margaret
|
DCEG (NCI)
|
|
Family Studies
|
ZIA CP004410-08285
|
$964,473
|
$48,224
|
A Tucker, Margaret
|
DCEG (NCI)
|
|
Family Studies
|
ZIA CP004410-10011
|
$16,987
|
$13,589
|
A Tucker, Margaret
|
DCEG (NCI)
|
|
Chemoprevention of arsenic-induced skin cancer
|
5R01CA107431-05
|
$1,579,984
|
$394,996
|
AHSAN, HABIBUL
|
UNIVERSITY OF CHICAGO
|
|
Participation in the Eastern Cooperative Oncology Group
|
5U10CA107868-06
|
$238,147
|
$19,052
|
AISNER, JOSEPH
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
ATBC Study
|
ZIA CP010195-03031
|
$804,186
|
$48,251
|
Albanes
|
DCEG (NCI)
|
|
Vitamin D Pooling Project
|
ZIA CP010195-10436
|
$398,953
|
$67,822
|
Albanes
|
DCEG (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$728,095
|
$36,405
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Children's Oncology Group Statistics and Data Center Grant
|
5U10CA098413-07
|
$5,725,544
|
$171,766
|
ANDERSON, JAMES
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Extension of Radiotherapy Research
|
3P01CA006294-44S1
|
$300,000
|
$30,000
|
ANG, K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
ADD ARTICLE H.49., EXCHANGE OF CONFIDENTIAL INFORMATION AND RESEARCH MATERIALS
|
N01CO800001-012
|
$231,187,932
|
$824,000
|
ARTHUR, LARRY
|
SAIC-FREDERICK INC:1107088
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-06A1
|
$2,300,000
|
$2,300,000
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-11
|
$130,866
|
$10,469
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
5R01CA077091-06
|
$346,857
|
$69,371
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-35
|
$417,370
|
$33,390
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
San Juan Minority - Based Community Clinical Oncology Program
|
5U10CA052667-19
|
$687,330
|
$13,747
|
BAEZ, LUIS
|
SAN JUAN HEALTH DEPARTMENT
|
|
The 50th Annual Meeting of the American Society of Pharmacognosy
|
1R13CA139768-01
|
$2,500
|
$750
|
BAKER, BILL
|
UNIVERSITY OF SOUTH FLORIDA
|
|
Southwest Oncology Group
|
5U10CA027057-30
|
$267,015
|
$2,670
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
SOUTHWEST ONCOLOGY GROUP - OPERATIONS OFFICE
|
5U10CA032102-30
|
$9,379,270
|
$93,793
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Clinical Studies to Circumvent Drug Resistance
|
ZIA BC 010620
|
$109,331
|
$27,333
|
Bates, Susan
|
CCR (NCI)
|
|
Investigation of the ABC Half-Transporter ABCG2
|
ZIA BC 010622
|
$382,659
|
$76,532
|
Bates, Susan
|
CCR (NCI)
|
|
The Gulf Coast MBCCOP
|
5U10CA128536-03
|
$507,986
|
$10,160
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
Iowa Oncology Research Association
|
5U10CA035101-24
|
$865,544
|
$17,311
|
Behrens, Robert
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
The role of Toll-like receptor 3 in overcoming cancer immunoediting
|
5K22CA122828-03
|
$162,035
|
$16,204
|
Bell, Jessica
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Eastern Cooperative Oncology Group Clinical Trials
|
5U10CA017145-34
|
$460,085
|
$36,807
|
BENSON, AL
|
NORTHWESTERN UNIVERSITY
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S2
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S5
|
$143,383
|
$1,434
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-45
|
$11,688,901
|
$116,889
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Geisinger Clinical Oncology Program
|
5U10CA035448-26
|
$610,000
|
$12,200
|
Bernath, Albert
|
WEIS CENTER FOR RESEARCH-GEISINGER CLINC
|
|
Studies of Medical Radiation and Other Therapeutic Agents
|
ZIA CP010131-04021
|
$64,057
|
$3,843
|
Berrington, Amy
|
DCEG (NCI)
|
|
Studies of Medical Radiation and Other Therapeutic Agents
|
ZIA CP010131-04033
|
$172,949
|
$17,295
|
Berrington, Amy
|
DCEG (NCI)
|
|
Genetics of pediatric rhabdoid tumors
|
5R01CA046274-18
|
$266,860
|
$90,732
|
BIEGEL, JACLYN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
|
Mechanisms of Renal Carcinogenesis
|
5R01CA131272-02
|
$225,901
|
$225,901
|
Block, Karen
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
|
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell Carcinoma
|
ZIA BC 011095
|
$29,318
|
$29,318
|
Bottaro, Donald
|
CCR (NCI)
|
|
Development of Grb2 SH2 Domain Antagonists as Anti-Cancer Therapeutics
|
ZIA BC 011123
|
$87,953
|
$43,977
|
Bottaro, Donald
|
CCR (NCI)
|
|
Oncogenic Met Signaling in Urologic Malignancies
|
ZIA BC 011124
|
$175,907
|
$14,073
|
Bottaro, Donald
|
CCR (NCI)
|
|
Late Effects of Treatment in Wilms Tumor Survivors and Offspring
|
5R01CA054498-18
|
$1,023,737
|
$1,023,737
|
BRESLOW, NORMAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein
|
5R01CA129387-02
|
$325,775
|
$325,775
|
Brugarolas, James
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
Southwest Oncology Group
|
5U10CA004919-50
|
$195,727
|
$1,957
|
BUDD, G
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Inhibitors of Tyrosine Kinase-Dependent Signalling as Anti-Cancer Agents
|
ZIA BC 006198
|
$701,769
|
$526,326
|
Burke, Terrence
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
3P30CA046934-22S1
|
$146,023
|
$2,920
|
Byers, Tim
|
UNIVERSITY OF COLORADO DENVER
|
|
Cancer Center Support Grant
|
3P30CA046934-22S2
|
$85,992
|
$1,720
|
Byers, Tim
|
UNIVERSITY OF COLORADO DENVER
|
|
Cancer Center Support Grant
|
5P30CA046934-22
|
$4,497,135
|
$89,943
|
Byers, Tim
|
UNIVERSITY OF COLORADO DENVER
|
|
Methylation & Proteomics-Based Detection of Renal Cancer
|
3U01CA111242-05S1
|
$282,254
|
$282,254
|
CAIRNS, PAUL
|
FOX CHASE CANCER CENTER
|
|
Innate Immunity: Elucidation and Modulation for Cancer Therapy
|
5P01CA095426-08
|
$2,044,559
|
$204,456
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Cancer Risk and Environmental Exposures
|
ZIA CP010125-02130
|
$60,154
|
$10,226
|
Cantor, Kenneth
|
DCEG (NCI)
|
|
Phase I Clinical Trials of New Anti-Cancer Targeted Therapies
|
5U01CA070095-15
|
$890,075
|
$80,107
|
CARDUCCI, MICHAEL
|
JOHNS HOPKINS UNIVERSITY
|
|
Effects of genetic polymorphism in MHC, KIR, and related loci on human disease
|
ZIA BC 010791
|
$875,336
|
$43,767
|
Carrington, Mary
|
CCR (NCI)
|
|
Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
|
1K08CA142890-01
|
$169,400
|
$169,400
|
Cho, Daniel
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
Total relevant funding to Kidney Disease for this search: $45,197,735
|